Nothing Special   »   [go: up one dir, main page]

CO5150150A1 - 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales - Google Patents

4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales

Info

Publication number
CO5150150A1
CO5150150A1 CO99081336A CO99081336A CO5150150A1 CO 5150150 A1 CO5150150 A1 CO 5150150A1 CO 99081336 A CO99081336 A CO 99081336A CO 99081336 A CO99081336 A CO 99081336A CO 5150150 A1 CO5150150 A1 CO 5150150A1
Authority
CO
Colombia
Prior art keywords
quinoleincarboxamidas
dihidro
oxo
antiviral agents
substituted
Prior art date
Application number
CO99081336A
Other languages
English (en)
Inventor
Steven Ronald Turner
Suvit Thaisrivongs
Valerie A Vaillancourt
Mark E Schnute
Allen Scott
Joseph Walter Strohbach
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CO5150150A1 publication Critical patent/CO5150150A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula I<EMI FILE="99081336_1" ID="1" IMF=JPEG >en donde,R1 es C1-7alquilo, opcionalmente substituido con hidroxilo o NR4R5; R2 es C1-7alquilo substituido con hidroxilo o NR4R5;R3 es H, F o C1-7 alcoxilo;R4 y R5 conjuntamente con N son un radical heterocíclico de 5 ó 6 miembros que tienen 1-3 heteroátomos seleccionados del grupo formado de nitrógeno, oxígeno y azufre, en el cual el azufre puede estar substituido por uno (1) o dos (2) átomos de oxígeno; y una sal farmacéuticamente aceptable del mismo.
CO99081336A 1999-01-08 1999-12-29 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales CO5150150A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11511399P 1999-01-08 1999-01-08
US13839099P 1999-06-09 1999-06-09
US14061499P 1999-06-23 1999-06-23

Publications (1)

Publication Number Publication Date
CO5150150A1 true CO5150150A1 (es) 2002-04-29

Family

ID=27381602

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99081336A CO5150150A1 (es) 1999-01-08 1999-12-29 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales

Country Status (28)

Country Link
US (1) US6248736B1 (es)
EP (1) EP1140851B1 (es)
JP (1) JP2002534417A (es)
KR (1) KR20010101428A (es)
CN (1) CN1132818C (es)
AT (1) ATE275134T1 (es)
AU (1) AU2158300A (es)
BR (1) BR9916781A (es)
CA (1) CA2353634A1 (es)
CO (1) CO5150150A1 (es)
CZ (1) CZ20012458A3 (es)
DE (1) DE69919897T2 (es)
EA (1) EA004043B1 (es)
ES (1) ES2228162T3 (es)
HK (1) HK1041879A1 (es)
HU (1) HUP0105142A3 (es)
ID (1) ID29452A (es)
IL (1) IL144170A0 (es)
MY (1) MY118904A (es)
NO (1) NO320396B1 (es)
NZ (1) NZ512823A (es)
PE (1) PE20001337A1 (es)
PL (1) PL348769A1 (es)
PT (1) PT1140851E (es)
SK (1) SK8312001A3 (es)
TR (1) TR200101893T2 (es)
TW (1) TW593281B (es)
WO (1) WO2000040563A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6682892B2 (en) * 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP1363887A1 (en) * 2001-03-01 2003-11-26 PHARMACIA &amp; UPJOHN COMPANY Substituted quinolinecarboxamides as antiviral agents
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
AR038294A1 (es) 2002-01-14 2005-01-12 Upjohn Co Oxotieno(3,2-b)piridincarboxamidas como agentes antivirales
AR038117A1 (es) 2002-01-14 2004-12-29 Upjohn Co Agentes antivirales derivados de la 4- oxo-4,7 -dihidrofuro [2,3-b]piridin-5-carboxamida
AR038118A1 (es) * 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US20040176366A1 (en) * 2002-08-30 2004-09-09 Wathen Michael W Method of preventing or treating atherosclerosis or restenosis
US20040186131A1 (en) * 2002-08-30 2004-09-23 Wathen Michael W Method of preventing or treating atherosclerosis or restenosis
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
ATE443048T1 (de) * 2002-11-20 2009-10-15 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
MXPA06000675A (es) 2003-07-24 2006-04-19 Astellas Pharma Inc Derivado de quinolona o sal del mismo.
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP2229945A1 (en) 2004-05-21 2010-09-22 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
EP2489659B1 (en) 2004-06-24 2017-12-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20070032522A1 (en) * 2005-07-01 2007-02-08 Kumar Dange V Antiviral agents
ES2790700T3 (es) 2005-12-28 2020-10-28 Vertex Pharma Composiciones farmacéuticas de la forma amorfa de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida
WO2007089030A1 (en) * 2006-02-01 2007-08-09 Japan Tobacco Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
US8383819B2 (en) * 2006-03-06 2013-02-26 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
DE102008036099B4 (de) 2008-08-04 2014-02-13 Steag Power Saar Gmbh Entstickungsanlage
AU2010226400B2 (en) 2009-03-20 2016-07-14 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
WO2011004389A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
TWI522349B (zh) * 2010-08-27 2016-02-21 歌林達股份有限公司 作為ｋｃｎｑ２／３調節劑之被取代之２－氧基－喹啉－３－甲醯胺
EP2819670A1 (en) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
EP2909193B1 (en) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Phenyl linked quinolinyl modulators of ror-gamma-t
EP2909189B8 (en) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Heteroaryl linked quinolinyl modulators of ror-gamma-t
EA026415B1 (ru) 2012-10-16 2017-04-28 Янссен Фармацевтика Нв Связанные с метиленом хинолиниловые модуляторы ror-гамма-t
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
KR20160070133A (ko) 2013-10-15 2016-06-17 얀센 파마슈티카 엔.브이. RORyt의 알킬 결합 퀴놀리닐 조절제
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
CN112996789A (zh) 2018-09-12 2021-06-18 诺华股份有限公司 抗病毒吡啶并吡嗪二酮化合物
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593810B1 (fr) * 1986-01-24 1988-04-22 Sanofi Sa Derives de la quinoleine, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
JPH06502845A (ja) * 1990-09-07 1994-03-31 シェリング・コーポレーション 抗ウイルス化合物および抗高血圧化合物
US5175151A (en) 1990-09-07 1992-12-29 Schering Corporation Antiviral compounds and antihypertensive compounds
DE69115692T2 (de) 1991-09-10 1996-08-01 Agfa Gevaert Nv Thermisch übertragbare fluoreszierende Verbindungen
CA2225552A1 (en) * 1995-08-02 1997-02-13 Chiroscience Limited Quinolones and their therapeutic use
AU7333496A (en) 1995-10-19 1997-05-07 Takeda Chemical Industries Ltd. Quinoline derivatives as gnrh antagonists
EP0944619B1 (en) 1996-11-27 2006-10-11 Bristol-Myers Squibb Pharma Company Novel integrin receptor antagonists
HUP0101999A3 (en) 1997-12-22 2003-06-30 Upjohn Co 4-hydroxyquinoline-3-carboxamides and hydrazides use of them and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CZ20012458A3 (cs) 2001-12-12
EP1140851B1 (en) 2004-09-01
CN1132818C (zh) 2003-12-31
SK8312001A3 (en) 2001-12-03
KR20010101428A (ko) 2001-11-14
AU2158300A (en) 2000-07-24
IL144170A0 (en) 2002-05-23
CN1332729A (zh) 2002-01-23
NZ512823A (en) 2003-10-31
BR9916781A (pt) 2001-12-04
DE69919897D1 (en) 2004-10-07
DE69919897T2 (de) 2005-09-08
EA200100755A1 (ru) 2001-12-24
HK1041879A1 (en) 2002-07-26
TR200101893T2 (tr) 2001-11-21
US6248736B1 (en) 2001-06-19
PT1140851E (pt) 2004-12-31
ID29452A (id) 2001-08-30
HUP0105142A2 (hu) 2002-04-29
PE20001337A1 (es) 2000-11-23
ATE275134T1 (de) 2004-09-15
WO2000040563A1 (en) 2000-07-13
EA004043B1 (ru) 2003-12-25
JP2002534417A (ja) 2002-10-15
NO20013379D0 (no) 2001-07-06
TW593281B (en) 2004-06-21
NO320396B1 (no) 2005-11-28
EP1140851A1 (en) 2001-10-10
MY118904A (en) 2005-02-28
HUP0105142A3 (en) 2002-05-28
CA2353634A1 (en) 2000-07-13
NO20013379L (no) 2001-07-06
PL348769A1 (en) 2002-06-17
ES2228162T3 (es) 2005-04-01

Similar Documents

Publication Publication Date Title
CO5150150A1 (es) 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales
CO5261589A1 (es) Compuestos heterociclicos, su produccion y su utilizacion
ATE402701T1 (de) N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino- - glucitol zur behandlung von hepatitis-virus- infektionen
AP1771A (en) 3&#39;-Prodrugs of 2&#39;-deoxy-?-L-nucleosides.
CO5251404A1 (es) Compuestos antibioticos de azalida
CO5300398A1 (es) Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek
TR200102805T2 (tr) Glikokinaz aktivatörleri
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
UY26093A1 (es) Inhibidores de ap2 de bifenilos que contienen compuestos heterociclicos y metodo
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
CO5180629A1 (es) Pirimidina-2,4,6-ttrionas inhibidores de metaloproteinasas
CO5690130A1 (es) Derivados de eter biarilico que presentan actividad como inhibidores de la recaptacion de monoaminas para el tratamiento del snc
NO20021395D0 (no) Kinazolinderivater
BRPI0515596A (pt) composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero
NO921609L (no) Sulfonamider og deres medisinske anvendelse
CO5271666A1 (es) Derivados de pirimidina
DE60318826D1 (de) Alkoxypyridinderivate
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
CO5251424A1 (es) Oxazinquinolonas utiles en el tratamiento de infecciones virales
ES2038754T3 (es) Agentes antiarritmicos.
PE20011028A1 (es) Combinacion oncolitica de acetildinalina y paclitaxel y/o carboplatino
ATE271542T1 (de) 2-thiocarbamoyloxy- und 2-carbamoyloxy-derivate von cyclopentyl-heptan(en)säure als therapeutische mittel
CO5210951A1 (es) Mezclas fungicidas sinergicas de una azolopirimidina y una fenoxiamida inhibidora de la biosisntesis de melanina
ECSP993294A (es) 4- oxo-1,4- dihidro -3-quinoleincarboxamidas como agentes antivirales
CO5140120A1 (es) Inhibidores de proteasas de 4-amino-azepan-3-ona